The new campaign stars former NFL quarterback Alex Smith, whose leg injury during a 2018 game led to a case of ...

New non-opioid pain killer get FDA approval for acute pain. Patients are taking note. Also demonstrated efficacy, just not ...

Vertex's medication, named Journavx, is seen as a major development in the ongoing effort to provide effective pain management solutions without the harmful consequences associated with opioid ...

Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

After you've had surgery or experienced a serious physical injury, you are more than likely going to be in a lot of pain. No matter what your pain tolerance is, recovering from surgery or any ...

The message is that Journavx is off to a strong start in its acute pain debut, with good momentum across hospital and retail settings and broad shelf availability, reportedly on close to 90% of U ...

Heading into 2025, an even bigger game changer for the company may be Journavx, approved in January by the FDA as the first oral non-opioid painkiller in its class. Journavx taps into a massive ...

Casgevy, approved in 2023, is a medicine for two rare, life-threatening blood disorders with few treatment options. Journavx is a medicine for acute pain -- though there are lots of options here, most ...

The oral NaV1.8 inhibitor has been cleared under the Journavx brand name with a broad label to treat adults with moderate-to-severe acute pain - for example, after trauma or surgery - and works by ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. One of these two impactful publications was ...

If that is a signal of reduced efficacy in chronic pain it could be a drag on Journavx peak sales potential, as that is a much larger market opportunity than acute pain. Vertex said it intended to ...